{"id":912028,"date":"2025-11-20T07:33:57","date_gmt":"2025-11-20T12:33:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/"},"modified":"2025-11-20T07:33:57","modified_gmt":"2025-11-20T12:33:57","slug":"briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/","title":{"rendered":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Collaboration uses Receptor AI&#8217;s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Partnership expected to expand BriaPro&#8217;s small-molecule pipeline <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Aims to accelerate the development of next generation therapeutics with improved efficacy and safety <\/em><br \/>\n          <\/strong><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov.  20, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announces that its subsidiary, BriaPro Therapeutics Corp. (\u201cBriaPro\u201d), has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications.<\/p>\n<p align=\"justify\">The collaboration will integrate AI-driven molecular design expertise and BriaPro\u2019s proprietary technology to expand BriaPro\u2019s small-molecule pipeline and accelerate the development of selective kinase inhibitors that may enhance immune-mediated tumor targeting and improve cancer patient outcomes.<\/p>\n<p align=\"justify\">\u201cThis partnership marks an important step in BriaCell\u2019s strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment,\u201d stated Dr. William V. Williams, President and CEO of BriaCell and BriaPro.<\/p>\n<p align=\"justify\">\u201cKinase selectivity, down to the isoform level, remains one of the hardest optimization problems in oncology,\u201d said Dr. Alan Nafiev, CEO and Founder of Receptor.AI. \u201cThis collaboration is about bringing disciplined, AI-first molecular design and rigorous ADMET constraints to BriaCell\u2019s oncology programs, enhancing precision and translational confidence from the earliest stages of discovery.\u201d<\/p>\n<p align=\"justify\">Receptor.AI has developed a multiplatform ecosystem for AI-enabled drug discovery, integrating small-molecule, peptide, and induced-proximity technologies into a unified framework that accelerates therapeutic innovation across modalities. Within the collaboration, Receptor.AI will harness its small-molecule discovery platform to drive target assessment, hit identification, and lead optimization, with a particular focus on achieving precise isoform selectivity among closely related kinases.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p>BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cnz7RgIF9RoGgJWRaeLyMkUhV3f1w-ryhLJMLeST2QtIv0Q7UHa_aRL_RYBx-a2l6obXGKVIYNJI7w9mm9jCOmwY9ekEMip4cC_pWYoXq04=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaPro Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaPro Therapeutics Corp. is a pre-clinical stage immunotherapy company developing binding agents and proteins designed to enhance the ability of the body\u2019s own cancer-fighting cells to eliminate tumors. BriaPro is a wholly owned subsidiary of BriaCell Therapeutics Corp.<\/p>\n<p align=\"justify\">\n        <strong>About Receptor.AI<\/strong>\n      <\/p>\n<p align=\"justify\">Receptor.AI is a next-generation TechBio company transforming drug discovery through AI-native infrastructure and deep modality expertise. With a validated track record across more than 40 discovery programs, the company integrates machine learning, physics-based modeling, and automated decision-making into a unified R&amp;D platform. Receptor.AI drives innovation across small molecules, peptides, and induced-proximity therapeutics, partnering with global biopharma and academic institutions to unlock challenging targets and accelerate the path from concept to clinic. More information is available at<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gd3OOAsZl7FXXUPEw93KdjcFrY6TDIxFkg8sqjI-ux6gbvYN_I3ptpljsX3JnDa51EV7c9uYzijNWhzFedp47lC6racdhuPiMzF9nXjqvzk=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.receptor.ai<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.<\/p>\n<p align=\"justify\">Forward-looking statements, including those about statements relating to the anticipated impact and results of Receptor.AI\u2019s collaboration with BriaCell, including any further commercial outcomes from the partnership. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PPmekn9GnmPHpnC8kUKpet0DUfI7n6Fa9RbHqp92i1DlNP2HNrUyIgePJTBgd3S_hxbouCAot2I4Odqa6CaAfwqczmk4HmlnOeiv86aGLHJ1kzxm5rLkSYYSkxPUnGyoQvNN3shCW1c87osRWpP3aI7N1eUf9AAdDrJhVJ2ubj1yfeGRqJPZKBb7go0GTluKyupKsRmaw46q4qbf2XBB3mhynKJ69Ib-1S7jZvN_-z4-m7heRJ2jGExpYz8ZXHCP5f_hEmt4Ce1a0GUnngmuzA==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca\u00a0<\/strong><\/a>and on EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PPmekn9GnmPHpnC8kUKpeq2f3OCwjIsNVhcvTRLklzkyYe--1pte3EbqvAffi8nLba7rfcgbYKlSTDQAZE0MkSbK-OwC3y0rBzx176XdYo-OFZTAmTyZXukMm2kfSj2wCBIjBGzy9orxzsJuYBP5JaL3VsbT8fwvl7rIblUfAvuC8YBlqxuKd8F-x1XvRzyVlwdVqaEIb7I-yFHYOknVj-iFxgW5VhlpP3e_9RM5Z5Q=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov\u00a0<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"justify\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MAdCRN4CbUoVDfZxpY7BO2CPA3pDwirWkvBK3aFtIUG59EsWCbOtJkDowmyzg4dbj6ZP-bYdAxfa1hjpp2CJIYHMX3lOXo_wrmi50_9DlznxhGOJqovbHjOAeMjdMqjHOsPriqBpNxlzEmR_44u5qFdl5nkP2cA871bO2Jyx9vYTatTq-6XNZAaA3V156qKsBVbduHlEzEi4JIT4JmliFNM9b49gAQ3ZwnJl-xLTBpRQBBA9uUypwhYwXNquDUcy3tY5XT94w1ncSaKwzS0bjQ==\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K4Qo376rLVNWlcjVgV0LN3G6PbbpS_Y5IDn2qZ2ZjQnZlnzQQBtce9_a083lI5kG91CLv7A3ZLt6OVdGQHczIB73TPwmyokK6CQ940qcTJIRdj6WodKKCwvsW9qzMP9nXZm8z6DCKroDh6eukB8WmIY_4_spqcPTl0PgnaEFilia38MPXODPUwVku8Mp174OunwHWUkXnS9-yQNSp4xfjS_vGi4VkyWStqwpN04vQD12aKOZwn6kN6iBNFSTT99t--5MXJ3_C8rIl33X11XWMg==\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTlhYjhhNDAtYWFhYS00Y2U1LTlmY2YtNjIwZTViOTkxOTNlLTExMDIyMjktMjAyNS0xMS0yMC1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration uses Receptor AI&#8217;s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro&#8217;s small-molecule pipeline Aims to accelerate the development of next generation therapeutics with improved efficacy and safety PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announces that its subsidiary, BriaPro Therapeutics Corp. (\u201cBriaPro\u201d), has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications. The collaboration will integrate AI-driven molecular design expertise and BriaPro\u2019s proprietary technology &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-912028","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Collaboration uses Receptor AI&#8217;s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro&#8217;s small-molecule pipeline Aims to accelerate the development of next generation therapeutics with improved efficacy and safety PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announces that its subsidiary, BriaPro Therapeutics Corp. (\u201cBriaPro\u201d), has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications. The collaboration will integrate AI-driven molecular design expertise and BriaPro\u2019s proprietary technology &hellip; Continue reading &quot;BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T12:33:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics\",\"datePublished\":\"2025-11-20T12:33:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/\"},\"wordCount\":775,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/\",\"name\":\"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=\",\"datePublished\":\"2025-11-20T12:33:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - Market Newsdesk","og_description":"Collaboration uses Receptor AI&#8217;s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro&#8217;s small-molecule pipeline Aims to accelerate the development of next generation therapeutics with improved efficacy and safety PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announces that its subsidiary, BriaPro Therapeutics Corp. (\u201cBriaPro\u201d), has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications. The collaboration will integrate AI-driven molecular design expertise and BriaPro\u2019s proprietary technology &hellip; Continue reading \"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-20T12:33:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics","datePublished":"2025-11-20T12:33:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/"},"wordCount":775,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/","name":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=","datePublished":"2025-11-20T12:33:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTIzNiM3Mjc0MTAwIzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-and-receptor-ai-to-collaborate-on-ai-driven-small-molecule-cancer-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/912028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=912028"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/912028\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=912028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=912028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=912028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}